List view / Grid view
The commercial production of recombinant proteins, such as antibodies and enzymes, relies on generating and maintaining specific cell lines designed to produce these specialised molecules. However, the creation of cell lines is a technically demanding and time-consuming process. For this reason, many businesses seek partnerships with contract development and manufacturing…
In this Q&A, Dr Nicholas Waters, Head of R&D at IRLAB, shares how three compounds, including IRLABs Mesdopetam and an experimental dopamine D3 receptor antagonist, could reverse features associated with the psychosis-like state of Parkinson’s disease.
Dr Christine Schuberth-Wagner serves as Chief Scientific Officer at CatalYm. She joined the company in November 2018 with more than 10 years of experience in drug discovery and non-clinical development of immunomodulatory drugs in the immuno-oncology space. She has established a track record as a successful leader and entrepreneur in the biotech…
Natural products play an underappreciated role in drug discovery. Tandem mass spectrometry (MS/MS)-based metabolomics coupled with machine learning is allowing new, highly diverse molecules from natural products to be identified, revealing bioactive compounds and pinpointing promising drug targets. The additional dimension provided by trapped ion mobility (TIMS) enables researchers to…
Join us for our Women in STEM series with Delphine Guyon-Gellin, Chief Business Development Officer at Osivax. She joined the company in 2018 with 15 years of experience in vaccine business and strategy. Prior to her work at Osivax, Delphine worked as a strategic consultant for leading pharmaceutical companies, helping…
In this Q&A, Aki Ko, CEO and co-founder of Elixirgen Therapeutics, elucidates how their new mRNA technology could potentially restore muscle function in those suffering from Duchenne muscular dystrophy.
Researchers have created a neutrophil therapy, involving micropatches that maintain the cells’ antitumour state, which could offer significant clinical and commercial value.
Despite significant strides in cancer research, metastasis remains the primary cause of cancer-related mortality globally. Joby Chesnick and Tracey Long, from the Digital Biology Group and Life Science Group, respectively, at BioRad Laboratories, reveal how investigation into circulating tumour cells (CTCs) and other rare cell types has led to the…
In this Q&A, Dr Murray Cairns, NHMRC Leadership Research Fellow at the University of Newcastle, shares his insights about the genetic influences on circulating retinol, and explains how a retinol polygenic score could be utilised in a precision medicine approach.
In this Q&A, Dr Vidmantas Šakalys, CEO of Vital3D, provides insights into the potential of 3D bioprinting to revolutionise the traditional drug development process, facilitating more accurate models and limiting the use of animal testing.
We had the privilege of talking to Dr Petra Dieterich, Senior Vice President at Abzena, about her highly successful career. After gaining her D.Phil in synthetic organic chemistry and an MBA from Imperial College London, she has held various leadership positions and has worked in the CRO and CDMO environment,…
Dr Anis H Khimani from Revvity explores how key developments have enhanced biotherapeutic workflows, and explores how a transposon system can aid stable clone development.
Introducing Kratherine Tran! Katherine joined the SCIEX team with a strong desire to further the company’s mission of delivering solutions to advance human wellness. Her main area of interest is within mass spectrometry-based proteomics from which she has accumulated a wealth of knowledge and experience in this space over the…
Thousands of bile acids have been discovered, providing new insights into how microbes influence distant organ systems.
A recent study has highlighted the impact of endotoxins on the accuracy of three-dimensional (3D) cancer models. In this Q&A, Dr Bjorn Vergauwen reveals details and key findings of the research.
